SGMO vs. GERN, MYGN, VSTM, LXRX, EBS, RIGL, XOMA, VNDA, IRWD, and CDXS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), and Codexis (CDXS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs. Its Competitors
Geron (NASDAQ:GERN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Geron has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
Geron presently has a consensus price target of $3.79, indicating a potential upside of 205.30%. Sangamo Therapeutics has a consensus price target of $4.50, indicating a potential upside of 581.82%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Geron.
Sangamo Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Geron has a net margin of -53.52% compared to Sangamo Therapeutics' net margin of -77.48%. Geron's return on equity of -31.37% beat Sangamo Therapeutics' return on equity.
73.7% of Geron shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 7.4% of Geron shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Geron had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for Geron and 1 mentions for Sangamo Therapeutics. Geron's average media sentiment score of 0.71 beat Sangamo Therapeutics' score of 0.59 indicating that Geron is being referred to more favorably in the media.
Summary
Geron beats Sangamo Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 10/23/2025 by MarketBeat.com Staff
